Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04164069 · ClinicalTrials.gov registry record · Phase 1
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
A Phase 1 study, sponsored by Anne Noonan.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04164069 is a Phase 1 study that has completed, run by Anne Noonan. The registered enrollment target is 9 participants.
The verdict
NCT04164069, a Phase 1 study, has completed, sponsored by Anne Noonan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This phase Ib trial studies side effects and best dose of dasatinib in preventing oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancers who are receiving FOLFOX regimen with or without bevacizumab. Drugs used in chemotherapy, such as leucovorin, fluorouracil, and oxaliplatin (FOLFOX regimen), work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. However, the buildup of oxaliplatin in the cranial nerves can result in damage or the nerves. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Blocking these enzymes may reduce oxaliplatin-induced peripheral neuropathy.
Interventions
- DRUG Fluorouracil
- DRUG Leucovorin
- DRUG Dasatinib
- BIOLOGICAL Bevacizumab
- DRUG Leucovorin Calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-09-02 |
| Est. Completion | 2023-06-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04164069
The ClinicalTrials.gov registry entry for NCT04164069 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anne Noonan, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fluorouracil is the first listed.
NCT04164069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04164069 about?
NCT04164069 is a clinical study titled "Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab". This phase Ib trial studies side effects and best dose of dasatinib in preventing oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancers who are receiving FOLFOX regimen with or without bevacizumab. Drugs used in chemotherapy, such as leucovorin, fluorouracil, and oxalip...
What is the current status of trial NCT04164069?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2020-09-02. Estimated completion is 2023-06-22.
What interventions are being tested in trial NCT04164069?
The interventions under investigation include: Fluorouracil (DRUG), Leucovorin (DRUG), Dasatinib (DRUG), Bevacizumab (BIOLOGICAL), Leucovorin Calcium (DRUG).
Who is sponsoring clinical trial NCT04164069?
This trial is sponsored by Anne Noonan, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.